Nanofiber Solutions
Ross Kayuha started their work experience in 1985 as a Senior Manager at Andersen Consulting. Ross then worked as a Senior VP at Claremont Technology Group from 1992 to 2000. From 2000 to 2008, they were the Owner of The Austin Group. In 2005, Ross became the CEO of Strategic Thinking Industries, where they worked until 2010. Starting in 2006, they also served as a Mentor at Ohio State University Center for Entrepreneurship until 2012. Ross joined Ohio TechAngel Fund in 2005 as a Member. In 2009, they became a Board Member at Brand Thunder and founded Nanofiber Solutions where they are currently the CEO.
Ross Kayuha obtained a Bachelor of Science in Business Administration with a major in Accounting from West Virginia University between the years 1976 and 1979. Following this, they pursued a Master of Business Administration with a concentration in Marketing from the University of Illinois Urbana-Champaign, completing their studies between 1983 and 1985. Additionally, Ross Kayuha received the certification of Certified Public Accountant from the State of West Virginia, although the specific month and year of obtaining this certification are not mentioned.
This person is not in any teams
This person is not in any offices
Nanofiber Solutions
1 followers
Nanofiber Solutions develops and markets electrospun nanofiber substrates for cell culture and drug development applications in standard multiwell plates or it can be scaled for larger configurations. Historically, general cell culture has been performed on flat, tissue culture polystyrene (TCPS) because it is cheap, optically clear, and many cellsgrow well on it. In reality, however, living organisms are made up of an extracellular matrix (ECM) that presents both aligned physical structure and mechanical support to the cells. Adherent cells are complex, self-sustaining units that require ECM anchorage to proliferate and undergo normal differential function. TCPS lacks this aligned three-dimensional (3-D) component and cells behave very differently on this flat, smooth substrate than they do in true biological settings. Not surprisingly, drugs developed using TCPS as an in vitro substrate experience a >99% failure rate in clinical studies.